Posts

Posted on

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

  • Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in high-risk patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
  • Extended follow-up data from EPCORE® NHL-1 trial demonstrates durability of responses and long-term safety of epcoritamab monotherapy for patients with challenging-to-treat relapsed/refractory (R/R) DLBCL
  • Both analyses were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH)

COPENHAGEN, Denmark–(BUSINESS WIRE)–Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), demonstrated an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in high-risk patients (n=46) with previously untreated DLBCL. Among complete responders, 83 percent remained in remission after two years. Separately, results from the Phase 2EPCORE® NHL-1 trial (NCT03625037), evaluating epcoritamab monotherapy in challenging-to-treat adult patients (n=157) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL; including 148 patients with R/R DLBCL), showed that among the 41 percent of patients who achieved a CR, an estimated 52 percent were still responding at three years (median CR duration: 36.1 months). Both analyses were presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH).

“The unprecedented durability of response seen in these data reinforce the potential of epcoritamab to become a core therapy for the treatment of multiple B-cell malignancies to benefit more patients,” said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. “These results support our ongoing Phase 3 trials for epcoritamab, including as an investigational first-line combination therapy in patients with previously untreated diffuse large B-cell lymphoma.”

EPCORE® NHL-2 Results in First-Line DLBCL (Abstract #581)

The EPCORE NHL-2 trial enrolled 46 patients considered to have high-risk DLBCL, identified by International Prognostic Index (IPI) scores of 3 to 5, a range associated with poor long-term outcomes. The IPI is a key tool used by oncologists to predict the prognosis of aggressive B-cell lymphomas.i At screening, 35 percent of patients (n=16) had bulky disease (>10 cm) and 21 percent (n=6) of evaluable patients (n=28) had double-hit/triple-hit LBCL based on gene rearrangements identified by central analysis.

  • With a median follow-up of 27.4 months (range, 0.8-33.9), 87 percent of patients remained alive at two years and 74 percent were progression free.

  • At two years, a minimal residual disease (MRD) analysis showed MRD negativity was achieved in 91 percent of evaluable patients (30/33), indicating no detectable disease.

  • Epcoritamab in combination with R-CHOP is being studied further in the ongoing, randomized, Phase 3 EPCORE DLBCL-2 trial (NCT05578976).

“More first-line treatment options for diffuse large B-cell lymphoma are needed, especially for patients with aggressive disease prognostic markers that may impact the efficacy of current standard first-line therapies,” said Lorenzo Falchi, MD, Lymphoma Specialist, Department of Medicine, Memorial Sloan Kettering Cancer Center.ii “Relapse rates with the R-CHOP treatment regimen can reach 50 percent, so the durable responses observed in the study suggest significant potential for this first-line epcoritamab-based combination.”

The most common treatment-emergent adverse events (TEAEs) were neutropenia (70 percent), anemia (69 percent), cytokine release syndrome (CRS; 60 percent), fatigue (49 percent), nausea (47 percent), pyrexia (42 percent), and injection-site reaction (40 percent). Four patients (9 percent) discontinued epcoritamab due to TEAEs; fatal TEAEs occurred in two patients (COVID-19 and septic shock). CRS events were mostly low grade (45 percent Grade 1, 11 percent Grade 2, 4 percent Grade 3) and mainly occurred after the first full dose. All CRS cases resolved, and none led to discontinuation. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in two patients (one Grade 1; one Grade 2) and resolved in a median of 2.5 days without leading to discontinuation.

Use of epcoritamab + R-CHOP in first-line DLBCL is not approved in the U.S. or in the EU or in any other territory. The safety and efficacy of epcoritamab for use as a combination therapy in DLBCL have not been established.

EPCORE® NHL-1 Results in Third-Line LBCL (Abstract #4480)

Three-year follow-up results from the Phase 2 EPCORE® NHL-1 trial evaluated epcoritamab monotherapy in 157 patients with R/R LBCL and demonstrated that epcoritamab continues to deliver durable responses in challenging-to-treat patients.

  • The ORR was 59 percent, and the CR rate was 41 percent. Median duration of response was 20.8 months (95 percent CI, 13.0-32.0) and median duration of CR was 36.1 months (95 percent CI, 20.2 to not reached [NR]).

  • 52 percent of patients who experienced a CR were still responding at three years (median CR duration: 36.1 months).

  • Of the 119 patients who were MRD-evaluable, 54 (45 percent) achieved MRD-negativity. In a cycle 3-day 1 landmark analysis, 3-year PFS rates were 52 percent among MRD-negative patients and 18 percent among MRD-positive patients.

The most common TEAEs were CRS (51 percent; 32 percent Grade 1, 16 percent Grade 2, 3 percent Grade 3), fatigue (25 percent), and pyrexia (25 percent); CRS rates remained unchanged since prior reports. Fatal TEAEs were reported in 20 patients; 10 patients had Grade 5 COVID-19 (including COVID-19 pneumonia). Seventy-three percent of patients treated with epcoritamab for two or more years did not experience a Grade 3 or higher infection after two years (median follow-up after 2 years, 12.3 months). Incidence of Grade 3 or higher cytopenias was highest (27 percent) during the first eight weeks of treatment and rates were within 0-13 percent in subsequent 12‑week time periods up to week 144. Immunoglobulin G levels decreased by a median of approximately 20 percent after the start of epcoritamab treatment (baseline median, 540.0 mg/dL) and remained stable over time.

About Diffuse Large B-Cell Lymphoma (DLBCL)

DLBCL is the most common type of non-Hodgkin’s lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.iii,iv In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year.v DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.vi,vii DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge. viii,ix

About the EPCORE® NHL-2 Trial

EPCORE® NHL-2 is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin’s lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary endpoint was overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint.

Arm 1 of the trial is epcoritamab plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‑CHOP) in adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 04663347).

About the EPCORE® NHL-1 Trial

EPCORE® NHL-1 is an open-label, multicohort, single-arm, Phase 1/2 trial of epcoritamab in participants with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL). The trial was conducted at 88 sites across 15 countries and consisted of three parts: a Phase 1 first-in-human, dose escalation part; a Phase 2a expansion part; and a Phase 2a dose optimization part. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 03625037).

About Epcoritamab

Epcoritamab is an IgG1-bispecific antibody created using Genmab’s proprietary DuoBody® technology and administered subcutaneously. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.x

Epcoritamab (approved under the brand name EPKINLY in the U.S. and Japan, and TEPKINLY in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication.

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigator’s choice chemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with R/R FL (NCT05409066), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.

EPKINLY® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

Important Warnings—EPKINLY can cause serious side effects, including:

  • Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
  • Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

  • Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
  • Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets.

In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Full Prescribing Information and Medication Guide, including Important Warnings.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About Genmab

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO™. EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.

i Maurer M. The International Prognostic Index in aggressive B-cell lymphoma. Haematologica. 2023 Nov 1;108(11):2874–2879. doi: 10.3324/haematol.2023.284070

ii Dr. Falchi has financial interests related to Genmab and AbbVie.

iii Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed November 2024. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/

iv Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.

v Leukemia and Lymphoma Society. Diffuse Large B-Cell Lymphoma (DLBCL). Accessed November 2024. https://www.lls.org/research/diffuse-large-b-cell-lymphoma-dlbcl

vi Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. doi: 10.1056/NEJMra2027612.

vii Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188.

viii Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. DOI: 10.1056/NEJMra2027612.

ix Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study. Blood. 2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.

x Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625.

David Freundel, Senior Director, Global R&D, Commercial & Portfolio Communications

T: +1 609 430 2481; E: [email protected]

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: [email protected]

KEYWORDS: Denmark Europe

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Oncology General Health Health Clinical Trials

MEDIA:

Logo
Logo
Posted on

Lamps Plus Partners with Manhattan to Improve Demand Forecasting, Inventory Accuracy

Lamps Plus Partners with Manhattan to Improve Demand Forecasting, Inventory Accuracy

ATLANTA–(BUSINESS WIRE)–Manhattan Associates Inc. (NASDAQ: MANH) announced today that Lamps Plus, the nation’s leading specialty lighting retailer, has implemented Manhattan’s Demand Forecasting and Inventory Optimization solution (DFIO) to improve forecast accuracy and visibility into replenishment cycles while maintaining demanding customer expectations.

Needing to upgrade its demand forecasting and inventory management capabilities, Lamps Plus selected Manhattan as part of an ongoing technology modernization effort. A longtime partner of Lamps Plus, Manhattan was the logical choice to expand its footprint with its best-in-class solution that harnesses the power of data analytics, machine learning and artificial intelligence to deliver unmatched forecast accuracy, even in the most complex and dynamic scenarios.

“Given the complexity and interdependence of demand forecasting and inventory management, and the critical importance of getting it right, we knew our legacy approach was no longer adequate to serve our business needs,” said Bill Gratke, chief supply chain officer at Lamps Plus. “Through our 17-year relationship with Manhattan, they’ve delivered time and again, which made this decision that much easier. This implementation was among the smoothest we’ve experienced, completed flawlessly in under six months.”

In addition to Demand Forecasting and Inventory Optimization, Lamps Plus has implemented Manhattan Active® Point of Sale, Store Inventory & Fulfillment, Order Management, Warehouse Management, Labor Management, and Slotting Optimization.

Lamps Plus has implemented Manhattan’s DFIO solution at its West Coast fulfillment center (FC) that serves its ecommerce channel as well as its 31 stores. A second FC on the East Coast will go live in the first half of 2025. It includes Manhattan’s Unified Forecasting Method, advanced statistical modeling designed to ensure the ideal state of “right inventory, right place, right time,” all the time.

As seasonality is a major factor in Lamps Plus’s business, Manhattan’s DFIO solution builds simulations that model the impact of seasonal demand on forecast accuracy before profiles are updated. With the improved forecast accuracy, Lamps Plus can confidently place orders months in advance to replenish stocks in late Q1/early Q2 2025, after the Chinese New Year vendor shutdown period.

Ecommerce represents a significant portion of Lamps Plus sales, and the company uses a shared inventory pool approach. With DFIO live at the FCs, Lamps Plus will be able to meet or exceed its fulfillment service levels while running leaner on inventory, saving on carrying costs and other operational expenses.

“We’ve had a long and successful partnership with Lamps Plus, including many successful transformational software projects,” said Stewart Gantt, executive vice president, Professional Services at Manhattan Associates. “With the addition of our DFIO solution, this leading retailer has improved its forecasting, providing significant gains in inventory segmentation and available to commerce (ATC) visibility.”

About Lamps Plus

Established in 1976 and headquartered in Los Angeles, Lamps Plus is the nation’s largest specialty lighting retailer, operating a thriving e-commerce business, LampsPlus.com, along with 35 stores in the western United States. Lamps Plus carries a full range of lighting and home furnishings, including exclusive patented designs and artisan-made customizable shades and lamps. The company’s American Lighting Association-trained staff provides expert advice. Follow @LampsPlus on social media: Instagram, Pinterest, YouTube, Facebook, TikTok, and X (formerly Twitter). To learn more about the history of the company, visit our About Us page.

About Manhattan Associates

Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers.

Manhattan Associates designs, builds and delivers leading edge cloud and on-premises solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.

Devika Goel

Manhattan Associates

Tel: +1 470-435-1566

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Data Management Supply Chain Management Technology Construction & Property Professional Services Interior Design Retail Data Analytics Software Artificial Intelligence Home Goods

MEDIA:

Posted on

Ameriprise Financial Names Brian Mora Senior Vice President of Experienced Advisor Recruiting

Ameriprise Financial Names Brian Mora Senior Vice President of Experienced Advisor Recruiting

MINNEAPOLIS–(BUSINESS WIRE)–
Ameriprise Financial, Inc. (NYSE: AMP) today announced that Brian Mora has been named Senior Vice President of Experienced Advisor Recruiting. Mora has more than 20 years with Ameriprise, most recently as regional vice president in the central region of the firm’s branch channel. In his new role, he will lead a nationwide team of recruiters and field leaders responsible for bringing quality experienced advisors from across the industry to Ameriprise. Mora will report to Pat O’Connell, President and Executive Vice President of the Ameriprise Branch & Institutions Groups.

“Brian brings an impressive track record of driving results and a genuine passion for advisor recruiting to this role,” said Pat O’Connell, President and Executive Vice President of the Ameriprise Branch & Institutions Groups. “Brian is well positioned to build on the firm’s recruiting success as he’s held a variety of leadership positions across our branch and independent channels – all of which will serve him and his new team well as they continue to attract top advisor talent to Ameriprise.”

“I’m honored to step into this role and bring our firm’s unmatched value to even more top advisors across the industry,” said Mora. “Ameriprise surrounds our advisors with the resources and support they need to deliver an outstanding client experience, stand out from the competition and achieve their growth goals. It’s a compelling value proposition backed by a firm with a 130-year track record of integrity and success.”

Mora holds a Bachelor of Science in Finance and Management from Montclair State University and a variety of professional designations including Certified Financial Planner (CFP), Chartered Retirement Planning Counselor (CRPC), and Accredited Wealth Management Advisor (AWMA).

Ameriprise has continued to attract experienced, productive financial advisors, with more than 400 advisors moving their practices to Ameriprise in 2023 and approximately 1,700 joining the firm in the last 5 years.1 To find out why experienced financial advisors are joining Ameriprise, visit ameriprise.com/why.

About the Ameriprise Ultimate Advisor Partnership

The Ameriprise Ultimate Advisor Partnership offers a differentiated experience for advisors that helps them accelerate growth while delivering an excellent client experience. Combined with the company’s culture of support and independence, the Ultimate Advisor Partnership enables advisors to scale their businesses, deepen client relationships and drive referrals for future growth.

About Ameriprise Financial

At Ameriprise Financial, we have been helping people feel confident about their financial future for 130 years. With extensive investment advice, asset management and insurance capabilities and a nationwide network of approximately 10,000 financial advisors2, we have the strength and expertise to serve the full range of individual and institutional investors’ financial needs.

Ameriprise Financial cannot guarantee future financial results.

Ameriprise Financial Services, LLC is an Equal Opportunity Employer.

Certified Financial Planner Board of Standards, Inc. (CFP Board) owns the CFP® certification mark, the CERTIFIED FINANCIAL PLANNER™ certification mark, and the CFP® certification mark (with plaque design) logo in the United States, which it authorizes use of by individuals who successfully complete CFP Board’s initial and ongoing certification requirements.

Investment products are not insured by the FDIC, NCUA or any federal agency, are not deposits or obligations of, or guaranteed by any financial institution, and involve investment risks including possible loss of principal and fluctuation in value.

Investment advisory products and services are made available through Ameriprise Financial Services, LLC, a registered investment adviser.

Securities offered by Ameriprise Financial Services, LLC. Member FINRA and SIPC.

© 2024 Ameriprise Financial, Inc. All rights reserved.

1 Ameriprise Financial 2023 10-K.

2 Ameriprise Financial Q2 2024 Earnings Release.

Alison Mueller, Media Relations

612.678.7183

[email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Personal Finance Finance Banking Professional Services Insurance

MEDIA:

Logo
Logo
Posted on

Roadzen Chosen by One of the World’s Largest LPG Carriers to Bring AI to its Fleet for Road Safety and Compliance

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN) (“Roadzen” or the “Company”), a global leader in AI at the convergence of insurance and mobility, today announced that a leading liquefied petroleum gas (LPG) supplier in India—a wholly owned subsidiary of one of the world’s largest LPG companies—will outfit its entire truck fleet with Roadzen’s drivebuddyAI. The system will monitor driver fatigue and provide real-time feedback to drive improvements in safety and compliance.

Roadzen’s drivebuddyAI was selected following a comprehensive five-month validation process, competing against the world’s leading video telematics and ADAS vendors. The contract, which carries a term of five years for more than 500 vehicles, is expected to deliver over seven figures in revenue over the term.

As the first system to receive Automotive Research Association of India (ARAI) certification under India’s Automotive Industry Standard 184, Roadzen’s DrivebuddyAI offers an unparalleled suite of advanced features designed to enhance driver safety, mitigate risks, improve driver performance, and optimize fleet operations. Leveraging state-of-the-art artificial intelligence and machine learning algorithms combined with video-telematics, DrivebuddyAI enables real-time monitoring, audio warnings and tagging recorded incidents, predictive analytics, and proactive collision avoidance capabilities. Featuring 98-point landmark tracking focused on the driver’s eye movement combined with 2-way communications, DrivebuddyAI is at the forefront of innovation for in-cabin analysis incorporating the most advanced safety features including distraction alert, drowsiness alert, focus monitoring, and emotion tracking capabilities.

Rohan Malhotra, founder and CEO of Roadzen, commented, “LPG suppliers and distributors care deeply about road safety due to the sensitive nature of cargo being transported. We’re seeing some of the leading players in this space adopt AI to enhance safety features across their fleets and reduce insurance premiums. As the first and only Advanced Driver Assistance System currently validated by the government of India to offer an integrable solution to vehicles seeking compliance with the AIS184 regulation— which is closely aligned with EU 2144 in Europe—we expect traction not just in India but also across European markets where safety and compliance remain top priorities. We’re looking at a highly active sales calendar for DrivebuddyAI and are fully prepared to meet the demand.”

For more information about Roadzen Inc. and DrivebuddyAI, please visit https://roadzen.ai/


About Roadzen Inc.

Roadzen Inc. (Nasdaq: RDZN) is a global technology company transforming auto insurance using advanced artificial intelligence (AI). Thousands of clients, from the world’s leading insurers, carmakers, and fleets, to dealerships, and auto insurance agents, use Roadzen’s technology to build new products, sell insurance, process claims, and improve road safety. Roadzen’s pioneering work in telematics, generative AI, and computer vision has earned Roadzen recognition as a top AI innovator by publications such as Forbes, Fortune, and Financial Express. Roadzen’s mission is to continue advancing AI research at the intersection of mobility and insurance, ushering in a world where accidents are prevented, premiums are fair, and claims are processed within minutes, not weeks. Headquartered in Burlingame, California, the Company has 379 employees across its global offices in the US, India, UK, and France. To learn more, please visit www.roadzen.ai

Media Contacts:

Sanya Soni: [email protected]
Gutenberg: [email protected]

Investor Contacts:

Yvonne Zappulla: [email protected]

Cautionary Statement Regarding Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “expected to,” “projected,” “begun to be adopted,” “accelerate the transformation,” “plan,” “anticipate,” “believe,” “estimate,” and “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, statements regarding our strategy, demand for our products, expansion plans, future operations, future operating results, estimated revenues, performance of our partnerships, losses, projected costs, prospects, plans and objectives of management, as well as all other statements other than statements of historical fact included in this press release. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in “Risk Factors” in our Securities and Exchange Commission (“SEC”) filings, including the definitive proxy statement/prospectus we filed with the SEC on August 14, 2023. We urge you to consider these factors, risks and uncertainties carefully in evaluating the forward-looking statements contained in this press release. All subsequent written or oral forward-looking statements attributable to our Company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included in this press release are made only as of the date of this release. Except as expressly required by applicable securities law, we disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



Posted on

CN Reaches New Tentative Collective Agreement with Unifor

MONTREAL, Dec. 09, 2024 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) announced today that a new tentative four-year collective agreement has been reached with Unifor. The union represents approximately 3,300 employees at CN in Canada, working in different mechanical, clerical, and intermodal functions.

No details of the tentative agreement will be released publicly until the agreement is ratified. The current collective agreement with Unifor expires on December 31, 2024.

About CN

CN powers the economy by safely transporting more than 300 million tons of natural resources, manufactured products, and finished goods throughout North America every year for its customers. With its nearly 20,000-mile rail network and related transportation services, CN connects Canada’s Eastern and Western coasts with the U.S. Midwest and the Gulf of Mexico, contributing to sustainable trade and the prosperity of the communities in which it operates since 1919. 



Contacts:



Media

Investment Community
Jonathan Abecassis Stacy Alderson
Director         Assistant Vice-President
Public Affairs and Media Relations Investor Relations
(438) 455-3692 (514) 399-0052
[email protected] [email protected]



Posted on

J.B. Hunt Participates in Wreaths Across America for 11th Consecutive Year

J.B. Hunt Participates in Wreaths Across America for 11th Consecutive Year

74 company drivers help transport company-record 356,000-plus wreaths to national cemeteries

LOWELL, Ark.–(BUSINESS WIRE)–
J.B. Hunt Transport Services Inc. (NASDAQ: JBHT), one of the largest supply chain solutions providers in North America, announced today its continued participation in Wreaths Across America for the 11th consecutive year. The nationwide effort ensures fallen veterans are remembered during the holiday season.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209117740/en/

To commemorate its 11th year of participating in Wreaths Across America, J.B. Hunt designed a custom wrap for select tractors and trailers featuring the theme, “Your Courage Inspires Us.” (Photo: Business Wire)

To commemorate its 11th year of participating in Wreaths Across America, J.B. Hunt designed a custom wrap for select tractors and trailers featuring the theme, “Your Courage Inspires Us.” (Photo: Business Wire)

“Wreaths Across America is a special time to recognize and honor military service members who sacrificed their lives for our freedoms,” said David Keefauver, executive vice president of people at J.B. Hunt. “This year marks a special milestone for J.B. Hunt – more than 500 company drivers have now participated in the effort throughout our 11 years of involvement, which demonstrates the commitment of our people to making sure no fallen veteran is forgotten during the holidays.”

This year, 74 J.B. Hunt drivers, all either veterans or have a direct association with a veteran, will help ensure that more than 356,000 wreaths make it to their final destination at national cemeteries across the country. On December 14, J.B. Hunt volunteers will join thousands across the nation for wreath-laying events on Wreaths Across America Day. The company will hold a ceremony on December 13 at its corporate headquarters for employees to celebrate its annual support and reflect on the non-profit organization’s mission to remember, honor and teach.

J.B. Hunt will haul 56 loads of wreaths this year, surpassing its record-setting total in 2023. This includes nearly 50 intermodal loads, which will be transported through ongoing collaborations with rail providers BNSF Railway and Norfolk Southern. To commemorate this year’s participation, the company has designed a custom wrap for 11 J.B. Hunt tractors and two J.B. Hunt trailers featuring the theme, “Your Courage Inspires Us”.

Altogether, J.B. Hunt will deliver 11 loads directly to 13 national cemeteries, including Abraham Lincoln National Cemetery, Dallas-Fort Worth National Cemetery, Dayton National Cemetery, Fayetteville National Cemetery, Fort Rosecrans National Cemetery, Georgia National Cemetery, Lexington National Cemetery, Marietta National Cemetery, National Memorial Cemetery of Arizona, Riverside National Cemetery, Salisbury National Cemetery, San Joquin Valley National Cemetery, and Tahoma National Cemetery, among others.

Wreaths Across America is one of many veteran-focused programs that J.B. Hunt participates in annually. The company also provides multiple opportunities that support the professional needs of employee veterans, including those transitioning to civilian life. This year, J.B. Hunt was honored with several national distinctions that include Top 10 Military Friendly® Employer by VIQTORY, America’s Greatest Workplaces for Veterans by Newsweek and Military Times Best for Vets.

About J.B. Hunt

J.B. Hunt’s vision is to create the most efficient transportation network in North America. The company’s industry-leading solutions and mode-neutral approach generate value for customers by eliminating waste, reducing costs and enhancing supply chain visibility. Powered by one of the largest company-owned fleets in the country and third-party capacity through its J.B. Hunt 360°® digital freight marketplace, J.B. Hunt can meet the unique shipping needs of any business, from first mile to final delivery, and every shipment in-between. Through disciplined investments in its people, technology and capacity, J.B. Hunt is delivering exceptional value and service that enable long-term growth for the company and its stakeholders.

J.B. Hunt Transport Services Inc. is a Fortune 500 company, an S&P 500 company and a component of the Dow Jones Transportation Average. Its stock trades on NASDAQ under the ticker symbol JBHT. J.B. Hunt Transport Inc. is a wholly owned subsidiary of JBHT. The company’s services include intermodal, dedicated, refrigerated, truckload, less-than-truckload, flatbed, single source, last mile, transload and more. For more information, visit www.jbhunt.com.

Brittnee Davie

Vice President – Marketing

[email protected]

KEYWORDS: Arkansas United States North America

INDUSTRY KEYWORDS: Other Transport Philanthropy Trucking Rail Maritime Air Other Philanthropy Transport Veterans Logistics/Supply Chain Management Defense

MEDIA:

Logo
Logo
Photo
Photo
To commemorate its 11th year of participating in Wreaths Across America, J.B. Hunt designed a custom wrap for select tractors and trailers featuring the theme, “Your Courage Inspires Us.” (Photo: Business Wire)
Posted on

SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of DMC Global Inc. (BOOM) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm 

ATLANTA, Dec. 09, 2024 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against DMC Global Inc. (“DMC Global” or the “Company”) (NASDAQ: BOOM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about DMC Global’s business, operations, and prospects, including allegations that: (i) the goodwill associated with Acadia Products was overstated due to the adverse events and circumstances affecting that reporting segment; (ii) DMC Global’s materially inadequate internal systems and processes were adversely affecting its operations; (iii) the Company’s inadequate systems and processes prevented it from ensuring reasonably accurate guidance and that its public disclosures were timely, accurate, and complete; and (iv) as a result, Defendants misrepresented DMC Global’s operations and financial results.

If you bought shares of DMC Global between May 3, 2024 and November 4, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/dmc-global/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is February 4, 2025.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]



Posted on

VEON Approves Launch of the Initial USD 30 Million Phase of its Share Buyback Program

Dubai and Amsterdam, 9 December 2024: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), announces that its Board of Directors has approved the commencement of the first phase of its previously announced share buyback program with respect to the Company’s American Depositary Shares (“ADS”). This first phase of the buyback will be in the amount of up to USD 30 million.

This USD 30 million first phase is part of VEON’s larger plan to execute a share  buyback program of up to USD 100 million. The buybacks will be conducted on the open market pursuant to a 10b5-1 plan signed with a registered broker-dealer, and in compliance with Rule 10b-18.

As stated in VEON’s announcement on 1 August 2024, the Company believes that its ADSs are undervalued relative to its operational performance and strategic potential.  By repurchasing ADSs, VEON aims to optimize shareholder value and strengthen its financial position for future opportunities.

Kaan Terzioglu, CEO of VEON Group, commented: “Our decision to initiate this share buyback program reflects the confidence we have in VEON’s growth trajectory and the value it delivers to shareholders. This program underscores our commitment to delivering long-term value while maintaining a disciplined approach to capital allocation.”

As noted in the Company’s 1 August 2024 announcement, the decisions on the timing and the specifics of the buybacks are subject to liquidity considerations, market conditions, applicable legal requirements, and other factors. Such factors have been taken into account in the approval process of the first USD 30 million phase of the program; and subsequent phases are expected to be carried out in the same manner, up to the authorized USD 100 million amount.

About VEON

VEON is a Nasdaq-listed digital operator that provides converged connectivity and digital services to nearly 160 million customers. Operating across six countries that are home to more than 7% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. For more information visit: www.veon.com.

Disclaimer

This release contains “forward-looking statements,” as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts, and include statements relating to, among other things, VEON’s initiation and continuation of its buyback program. Forward-looking statements are inherently subject to risks and uncertainties, many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update, except as required by U.S. federal securities laws, any forward-looking statement to reflect events or circumstances after such dates or to reflect the occurrence of unanticipated events. There can be no assurance that the initiatives referred to above will be successful.

Contact Information 

Hande Asik 
Group Director of Communications 
[email protected]

Faisal Ghori 
Group Director of Investor Relations 
[email protected]


 



Posted on

Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board

Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB).

Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of therapies for people with neurological disorders such as ALS. She is one of the founders and co-directors of the Northeast ALS (NEALS) Consortium, a group of over 150 clinical sites in the United States and Canada dedicated to performing collaborative, academic-led clinical trials in ALS subjects.

In welcoming Dr. Cudkowicz to the SAB, Dr. Joseph Sinkule, the Founder, CEO, and Chairman of Klotho Neurosciences commented: “Dr. Cudkowicz is clearly a world-renowned clinician and authority in the field of ALS, which is also often referred to as Lou Gehrig’s disease. We are honored to have her join our SAB and help guide us in clinical trial design and execution. We firmly believe that the Company’s gene therapy approach could be an important advance in the treatment of ALS using our patent-protected product candidate expressing the Klotho gene transcribed protein called ‘s-KL’ or “secreted Klotho.”

In responding, Dr. Cudkowicz expressed her appreciation for the invitation to join the SAB, stating that “It is vitally important that a company like Klotho Neurosciences receives the full support and guidance from members of their SAB to maximize the opportunity to expeditiously develop a safe and effective new treatment for ALS based on the Company’s proprietary s-KL. There is a clear and absolute urgent need for new and effective treatments for this devastating, universally-fatal disease, and I hope to be able to assist Klotho Neurosciences along the path to success.”

About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biopharmaceutical company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the “anti-aging” human Klotho gene and it’s novel delivery system (s-KL/AAV.myo) to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:

Eric Boyd

Investor Relations

Email: [email protected]

Website: www.klothoneuro.com

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.



Posted on

Principal® Recognized in Pensions & Investments’ Best Place to Work in Money Management for 13th Consecutive Year

Principal® Recognized in Pensions & Investments’ Best Place to Work in Money Management for 13th Consecutive Year

DES MOINES, Iowa–(BUSINESS WIRE)–Principal Asset Management℠, the investment management unit of Principal Financial Group®, announced today Pensions & Investments named the firm 2024 Best Place to Work in Money Management. This is the 13th consecutive year Principal has been recognized as a best place to work in the “largest employers” category, earning the recognition every year since the program’s inception.

“Building a strong asset management firm isn’t just about managing investments – it’s about creating a global culture where our team thrives on personal engagement, grows together with our clients, and is empowered to transform our platform,” said Kamal Bhatia, president and CEO, Principal Asset Management. “As workplace expectations continue to evolve, our employees and leaders remain committed to fostering an organization that is a cultural role model. Being named a Best Place to Work in Money Management isn’t easily achieved, and we are very proud to be recognized again.”

This recognition continues to highlight the commitment from Principal Asset Management to foster a collaborative workplace culture and prioritize employee engagement and innovation. The firm provides employees with a range of programs designed to foster a strong, supportive and inclusive workplace, including flexible work arrangements, a global mentoring program to encourage career growth, and comprehensive wellness initiatives. These efforts underscore the dedication of Principal to engage employees and deliver impactful solutions for clients worldwide.

About Pensions & Investments’ Best Place to Work in Money Management

Presented by Pensions & Investments, the global news source of money management and institutional investing, the 13th annual survey and recognition program is dedicated to identifying and recognizing the best employers in the money management industry.

The first part of the award consideration process included evaluating each nominated company’s workplace policies, practices, philosophy, systems, and demographics. This part of the process was worth approximately 20% of the total evaluation. The second part consisted of an employee survey to measure the employee experience. This part of the process was worth approximately 80% of the total evaluation. The combined scores determined the top companies.

For a complete list of the 2024 Pensions & Investments’ Best Places to Work in Money Management winners and the profiles of the top firms across size categories, go to http://www.pionline.com/BPTW2024.

About Principal Asset Management℠

With public and private market capabilities across all asset classes, Principal Asset Management and its investment specialists look at asset management through a different lens, creating solutions to help deliver client investment objectives. By applying local insights with global perspectives, Principal Asset Management identifies distinct and compelling investment opportunities for more than 1,100 institutional clients in over 80 markets.1 Principal Asset Management is the global investment solutions business for Principal Financial Group® (Nasdaq: PFG), managing $585.6 billion in assets1 and recognized as a “Best Places to Work in Money Management”2 for 13 consecutive years.

Learn more at www.PrincipalAM.com.

[1] As of September 30, 2024

[2] Pensions & Investments, “The Best Places to Work in Money Management”, among companies with 1,000 or more employees, December 2024.

©2024 Principal Financial Services, Inc., Principal®, Principal Financial Group®, Principal Asset Management, and Principal and the logomark design are registered trademarks and service marks of Principal Financial Services, Inc., a Principal Financial Group company, in various countries around the world and may be used only with the permission of Principal Financial Services, Inc. Principal Asset Management℠ is a trade name of Principal Global Investors, LLC. Principal Real Estate is the trade name of Principal Real Estate Investors, LLC, an affiliate of Principal Global Investors.

About Pensions & Investments

Pensions & Investments, owned by Crain Communications Inc., is the 51-year-old global news source of money management and institutional investing. P&I is written for executives at defined benefit and defined contribution retirement plans, endowments, foundations, and sovereign wealth funds, as well as those at investment management and other investment-related firms. Pensions & Investments provides timely and incisive coverage of events affecting the money management and retirement businesses. Visit us at www.pionline.com.

Media Contact:

Erin Parro

[email protected]

515-878-0130

KEYWORDS: United States North America Iowa

INDUSTRY KEYWORDS: Professional Services Other Professional Services Finance Asset Management Consulting Banking Personal Finance

MEDIA:

Logo
Logo